Success Story

Non-contact, non-radiation device for implant detection

(Developed by Dr Jason Pui Yin Cheung, Dr Teng Grace Zhang and Dr Weichen Qi, School of Clinical Medicine of HKU)

Latest Patents Filings
Event Highlights
Technology Commercialisation
Cases of adolescent idiopathic scoliosis (AIS) are on the rise in China, with studies showing that it is now the third biggest threat to children’s health, after obesity and myopia.

Severe scoliosis can have serious consequences, which include cosmetic deformations, restricted heart and lung function, and early death. In such cases, surgical correction is required. In young patients, growing rods are required to correct the deformity while guiding spinal growth.

Before and during surgery, detailed assessment and decision-making is required to ensure safe, accurate and effective treatment for growing children. This is typically conducted by radiographic examinations. However, radiographic machines have several disadvantages, particularly when dealing with children. The machines are large and cumbersome, and expose children to radiation. For growing implants, once treatment starts, radiographs are incapable of quantitatively assessing spatial changes of the surgical implants in 3D as children grow. These shortcomings make it difficult for surgeons to evaluate treatment outcomes.

A new, handheld device has now been invented that resolves these problems. The OI-GPS is a contactless, radiation-free multi-targets magnetic sensing technology that precisely locates the spatial coordinates of orthopaedic surgical implants in the patient’s body. It generates a 3D imaging model to allow a fast and accurate update of the condition of the spinal instrumentation, progress for correction and implant lengthening, and timely warnings of any mechanical faults.

During surgery, the surgeon places magnetic positioning beacons at the head of each screw. When assessing changes in the patient’s condition, the surgeon uses the handheld probe to easily visualise the 3D location of the implants on the spine using these magnetic beacons with millimeter level accuracy. During each assessment, the surgeon can quickly compare the 3D model with previous models during each treatment session, allowing the doctor to update the treatment plan without delay, leading to improved outcomes for patients.

The system also improves safety by providing timely warning of any mechanical problems, such as crooked rods, slippage or screw loosening.

The technology can also be used to evaluate the effectiveness of limb-lengthening surgery and to assist with positioning tracking of surgical instruments during procedures.

The new technology was developed by the research team of Dr Jason Pui Yin Cheung, Dr Teng Grace Zhang and Dr Weichen Qi from the Department of Orthopaedics & Traumatology, School of Clinical Medicine of HKU.

The invention won a silver medal at the Geneva International Exhibition of Inventions 2022 awards.

The TTO helped the team with the patent application for the invention. The TTO also chose this project for submission to the Geneva 2022 exhibition, and selected the invention for showcasing at the upcoming Innocarnival exhibition.
**EVENT HIGHLIGHTS**

Prof ZI Max Shen, HKU’s Vice-President and Pro-Vice-Chancellor (Research), Prof Ho Cheung (Anderson) Shum, Associate Vice-President (Research and Innovation), and Dr Shawn Zhao, Deputy Director of HKUTTO, attended the Launch Ceremony of the Innovation Hub@HK Website on 18 Aug. Prof Shen illustrated the research achievements of HKU, and introduced one invention “a photosresponsive nano drug delivery system” developed by Dr Weiping Wang and his research team.

Our next webinar is entitled “Old Drug, New Use: A Patent Infringement of Pharmaceutical Use Claims.” Expert speaker, Hsu Min Chung (Partner, HGF Limited), specialises in patents in chemistry, material science and pharmaceuticals. She will present an overview of case law and share advice for companies operating in this area. Wednesday, September 7, 4pm-5pm on Zoom. Click here to register.

---

**TECHNOLOGY COMMERCIALISATION**

List of technologies Licensed in July 2022

<table>
<thead>
<tr>
<th>Item</th>
<th>IP Type</th>
<th>PI</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compounds and uses thereof for treating inflammation and modulating immune responses</td>
<td>US, AU, CA, CN and JP granted patents</td>
<td>Prof. Allen Lau</td>
<td>Medicine</td>
</tr>
<tr>
<td>Method for isolating cimiracemate A</td>
<td>US, EP, AU, CA, CN, HK and JP granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel therapeutic methods for treating inflammation and immune system disorders</td>
<td>US, EP and HK granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Materials and methods for prevention and treatment of viral infections</td>
<td>AU, CN, EP, JP, CA, HK granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uses of cimiracemate A and related compounds for treating inflammation and modulating immune responses</td>
<td>CN and HK granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coriolus versicolor extracts, methods of preparation and uses thereof</td>
<td>US, AU, JP, EP, CA, HK and CN granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compounds and uses thereof for treating inflammation and modulating immune responses</td>
<td>US, CN, TW, CA, EP and HK granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coriolus versicolor extracts, methods of isolating biologically-active compounds, and uses thereof</td>
<td>US, AU, JP and TW granted patents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Materials and methods for prevention and treatment of viral infections</td>
<td>US, AU and JP granted patents</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Top 3 revenue-booked IPs in July 2022

<table>
<thead>
<tr>
<th>Item</th>
<th>IP Type</th>
<th>PI</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Construction and real estate policy analysis</td>
<td>Contract Research/Consultancy</td>
<td>Prof. KW Chau</td>
<td>Architecture</td>
</tr>
<tr>
<td>Longevity risk evaluation model development</td>
<td>Contract Research/Consultancy</td>
<td>Dr. Kwok Fai Lam</td>
<td>Statistic &amp; Actuarial Science</td>
</tr>
<tr>
<td>Anti-SARS-CoV-2 compounds</td>
<td>Contract Research/Consultancy</td>
<td>Dr. Shuofeng Yuan</td>
<td>Medicine</td>
</tr>
</tbody>
</table>
TRANSFERRING YOUR NEW TECHNOLOGIES INTO BUSINESS OPPORTUNITIES

POLICY STIPULATION

The latest policy stipulates that the net receipts arising from the exploitation of an Invention are shared among the University, the relevant faculty/department and the inventor(s) in the ratio of 1/3 : 1/3 : 1/3. It aims to encourage the researchers at HKU not only to excel in academic performance but also to apply their technology for the benefits of mankind with an impressive reward.

HOW TO APPLY:

4 PHASES FOR RESEARCH PROJECTS

Phase 1: Initial project negotiation
1. PI will negotiate with their collaborator(s) and confirm a project proposal which includes the scope, budget and duration of the project.
2. PI will negotiate with their collaborator(s) and prepare a draft agreement (Agreement templates are available at the website of the Research Services (RS): http://www.rss.hku.hk/contracts/contractresearch/templates).

Phase 2: Endorsement from department/faculty
3. PI will submit the project proposal, the draft agreement, and the information form/grant application form to their department/faculty to seek an approval (The information form for research/consultancy agreements is available at: http://intraweb.hku.hk/local/rss/tto/researchor-consultancy-agreements-form.doc).
4. After obtaining the approval, PI will submit the project proposal, the draft agreement, and the information form/grant application form to the Research Service (RS).

Phase 3: Financial legal/IP review
5. The RS will distribute the project proposal and the draft agreement to the Finance and Enterprises Office (FEO) for financial review and to the Technology Transfer Office (TTO) for legal review.
6. If there is any financial/legal issue, the FEO/TTO will inform PI through the RS. PI will negotiate with their collaborator(s) on the financial/legal issue until it is settled.

Phase 4: Signature and document archiving
7. After consolidating the settled project proposal and the agreement, the RS will proceed to the signature process.
8. After duly performing the signature process, the RS will assign the RCGAS number(s) for opening the project account(s).

ABOUT US

About HKUTTO
The Technology Transfer Office (TTO) is committed to maximising the impact of research through technology transfer at both the institutional and industrial levels. TTO works closely with researchers at HKU to commercialise their inventions through professional consultation on business development, legal advice and assistance, as well as patent application filings. Your inventions will not benefit society unless they are mass produced.

About Versitech
Versitech Limited is the commercial arm of HKU. Versitech negotiates, executes and manages commercial business contracts and agreements on behalf of the University.

CONTACT US

Acting Director
Prof. Max Shen
Email: vp-research@hku.hk

Deputy Director
Dr. Shawn Zhao
Email: xzhaogs@hku.hk

Senior Legal Counsel
Ms. Vivian Ng
Tel: 3917-3161
Email: vivian@tto.hku.hk

Manager, Business Development (Science & Engineering)
Ms. Laura Yu
Tel: 3917-3194
Email: laura@tto.hku.hk

Senior Manager, Business Development (Biotechnology)
Dr. Katherine Gan
Tel: 3917-3173
Email: katherine@tto.hku.hk

Intellectual Property Manager
Ms. Cindy Tung
Tel: 3917-3106
Email: cindytung@tto.hku.hk

Finance and Administration Manager
Ms. Joanne Cho
Tel: 3917-3177
Email: joanne@tto.hku.hk

SHARE YOUR SUCCESS STORY
Feel free to send us your story at tto_marketing@tto.hku.hk